Lesson From Antagonizing the Cellular Effects of Thrombin–Acute Coronary Syndromes - LANCELOT–ACS


Atopaxar is a novel protease-activated receptor-1 (PAR-1) antagonist (formerly known as E5555) that has shown promising results in early clinical studies. The LANCELOT−ACS trial was a phase II trial designed to study the safety and efficacy of atopaxar in patients admitted with acute coronary syndrome (ACS).